In the article, “Prevention and management of transplant-associated diabetes,” by Jenssen and Hartmann (Expert Opin Pharmacother 2011;12(17): 2641-55), an error has been identified. In Section 7.2.6 on page 10, some errors were identified in the sentences “A fourth DDP-inhibitor, piogliptin, is soon to be launched,” and “With the exception of piogliptin, the DPP-4 inhibitors are excreted by the kidneys, saxagliptin after being metabolized by the CYP 3A4 system, which is of concern for possible interaction with CNIs.” The correct sentences are “A fourth DDP-inhibitor, linagliptin, is soon to be launched,” and “With the exception of linagliptin, the DPP-4 inhibitors are excreted by the kidneys, saxagliptin after being metabolized by the CYP 3A4 system, which is of concern for possible interaction with CNIs,” respectively.
Informa Healthcare and the authors of this article would like to apologize for any confusion caused.